Fagron Liabilities 2024

Fagron Aktienanalyse

What does Fagron do?

Fagron NV is an internationally operating company that focuses on the development and production of customized medications for pharmacies and hospitals. The company was founded in 1990 in Rotterdam, Netherlands. The beginnings of Fagron NV were in the Netherlands, where the company was established as Roterodamum Chemie BV. In the late 1990s, the company was converted into a holding company called Arseus NV, which later received the name Fagron. In 2012, Fagron was listed on the Euronext stock exchange in Brussels. Fagron operates globally and has locations in Europe, North America, Latin America, the United Arab Emirates, Asia, and Australia. Fagron's business model is based on the production of specialized medications for individual patient needs. The company offers a wide range of pharmaceutical active ingredients, raw materials, and processing services. There is also the possibility to develop and manufacture customized formulations tailored to the needs of patients. Fagron not only manufactures customized medications but also provides training and support for pharmacies and hospitals. Fagron operates in three main divisions: Specialty Pharma (hospital care), Community Pharma (prescription and non-prescription medications), and Compounding Services (custom formulations). The Specialty Pharma division specializes in medications for use in hospitals. It offers a wide range of products that can be used in the treatment of conditions such as cancer, HIV, and tuberculosis. These medications are manufactured in various dosage forms, such as injections, infusions, and tablets. The Community Pharma division focuses on prescription and non-prescription medications. Both branded and generic medications are offered. These are delivered directly to pharmacies, hospitals, and clinics. The Compounding Services division specializes in the production of customized medications. Fagron works closely with pharmacies and hospitals to meet individual needs. This includes, for example, the manufacture of medications in specific dosages or the combination of several active ingredients in a custom formulation. Fagron offers a wide range of products, including hormones, pain medications, cancer drugs, medications for the treatment of skin diseases, ophthalmic products, and anti-infectives. Pharmaceutical active ingredients and raw materials are also offered. Overall, Fagron is a global leader in the production of customized medications. It has extensive experience and expertise in the manufacturing of pharmaceutical formulations and offers a wide range of products and services. The various divisions of Fagron allow the company to meet the diverse needs of its customers and maintain its position as a leading company in the pharmaceutical industry. Fagron ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Fagron's Liabilities

Fagron's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Fagron's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Fagron's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Fagron's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Fagron’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Fagron stock

What is the level of liabilities of Fagron this year?

Fagron has a debt balance of 543.2 M EUR this year.

What were the liabilities of Fagron compared to the previous year?

The liabilities of Fagron have increased by -4.11% dropped compared to the previous year.

What are the consequences of high debt for investors of Fagron?

High liabilities can pose a risk for investors of Fagron, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Fagron?

Low liabilities mean that Fagron has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Fagron affect the company?

An increase in liabilities of Fagron can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Fagron affect the company?

A decrease in the liabilities of Fagron can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Fagron?

Some factors that can influence the liabilities of Fagron include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Fagron so important for investors?

The liabilities of Fagron are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Fagron take to modify the liabilities?

To change its liabilities, Fagron can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Fagron pay?

Over the past 12 months, Fagron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fagron is expected to pay a dividend of 0.28 EUR.

What is the dividend yield of Fagron?

The current dividend yield of Fagron is .

When does Fagron pay dividends?

Fagron pays a quarterly dividend. This is distributed in the months of June, June, June, June.

How secure is the dividend of Fagron?

Fagron paid dividends every year for the past 0 years.

What is the dividend of Fagron?

For the upcoming 12 months, dividends amounting to 0.28 EUR are expected. This corresponds to a dividend yield of 1.57 %.

In which sector is Fagron located?

Fagron is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fagron kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fagron from 5/23/2024 amounting to 0.3 EUR, you needed to have the stock in your portfolio before the ex-date on 5/21/2024.

When did Fagron pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Fagron in the year 2023?

In the year 2023, Fagron distributed 0.2 EUR as dividends.

In which currency does Fagron pay out the dividend?

The dividends of Fagron are distributed in EUR.